Research programme: targeted protein degradation therapeutics - C4 Therapeutics

Drug Profile

Research programme: targeted protein degradation therapeutics - C4 Therapeutics

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator C4 Therapeutics
  • Developer Dana-Farber Cancer Institute
  • Class Small molecules
  • Mechanism of Action Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Mar 2017 C4 Therapeutics and Calico enter into a five year collaboration agreement to discover, develop and commercialise targeted protein degradation therapeutics for Cancer
  • 07 Jan 2016 C4 Therapeutics and Roche will develop TPD therapeutics for Cancer
  • 01 Jun 2015 Early research in Cancer in USA (unspecified route) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top